Document:

Exhibit
10.24

 

Second
Amendment to Transaction Documents

 

This
Second Amendment to the Transaction (this “Amendment”) is effective as of October 2, 2022 (“Effective Date”),
by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology,
Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate Blvd., Suite
110 Boca Raton, FL 33431, each a “Party” and collectively the “Parties”. Capitalized terms used
herein without definition shall have the meanings ascribed to them in the Securities Purchase Agreement, dated as of March 2, 2022, as
amended, entered between the Parties (the “Securities Purchase Agreement”)

 

Recitals

 

WHEREAS,
pursuant to the Transaction Documents, Puritan Partners purchased a 12.5% Original Issue Discount Senior Secured Note in the principal
amount of $1,142,857.14 due March 2, 2023 (the “Note”) and was issued a common stock purchase warrant to purchase 22,857,143
shares of the common stock at $0.0001 exercise price (the “Warrants”);

 

WHEREAS,
Puritan Partners and Company are parties to the Transaction Documents, which were previously amended on August 18, 2022 and the parties
now desire to further amend the respective Transaction Documents in accordance with the terms of this Amendment.

 

NOW,
THEREFORE, in consideration of the following and other consideration, the receipt of which is hereby acknowledged, the parties agree
as follows:

 

		(a)	Monthly
                                            Redemption Date. The definition of “Monthly Redemption Date” set forth in Section
1 of the Note is deleted in its entirety and hereby replaced with the following:

 

“Monthly
Redemption Date” means the second of each month commencing in October 2022; provided that the first Monthly Redemption Date
shall be October 17, 2022, and terminating upon the full redemption of this Note. Provided however that upon completion of a Qualified
Offering, the enter outstanding balance of the Note will be due and payable at closing of the Qualified Offering.

 

		(b)	The
                                            interest on the Note that is due and payable on October 2, 2022, shall instead be due and
                                            payable on the earlier of (i) October 17, 2022 and (ii) the closing of the Qualified Offering.

 

[Remainder
of Page Intentionally Left Blank]

 

    	 

    	 

    

 

Each
of the undersigned has caused this Amendment to be duly executed and delivered as of the date first written above and will become effective
as of the Effective Date.

 

	 	CURATIVE BIOTECHNOLOGY, INC.
	 	 	 
	 	By:	 
	 	Name:	Richard
    Garr                  
	 	Title:	Chief
    Executive Officer

 

	 	Puritan Partners LLC
	 	 	 
	 	By:	 
	 	Name:	Richard
    Smithline
	 	Title:	Managing
    MemberExhibit
10.25

 

Third
Amendment to Transaction Documents

 

This
Third Amendment to the Transaction (this “Amendment”) is effective as of October 14, 2022 (“Effective Date”),
by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology,
Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate Blvd., Suite
110 Boca Raton, FL 33431, each a “Party” and collectively the “Parties”. Capitalized terms used
herein without definition shall have the meanings ascribed to them in the Securities Purchase Agreement, dated as of March 2, 2022, as
amended, entered between the Parties (the “Securities Purchase Agreement”)

 

Recitals

 

WHEREAS,
pursuant to the Transaction Documents, Puritan Partners purchased a 12.5% Original Issue Discount Senior Secured Note in the principal
amount of $1,142,857.14 due March 2, 2023 (the “Note”) and was issued a common stock purchase warrant to purchase 22,857,143
shares of the common stock at $0.0001 exercise price (the “Warrants”);

 

WHEREAS, Puritan
Partners and Company are parties to the Transaction Documents, which were previously amended on August 18, 2022 and October 2, 2022
and the parties now desire to further amend the respective Transaction Documents in accordance with the terms of this
Amendment.

 

NOW,
THEREFORE, in consideration of the following and other consideration, the receipt of which is hereby acknowledged, the parties agree
as follows:

 

		a)	Monthly
                                            Redemption Date. The definition of “Monthly Redemption Date” set forth in Section
1 of the Note is deleted in its entirety and hereby replaced with the following:

 

“Monthly
Redemption Date” means the second of each month, commencing immediately upon November 2, 2022, and terminating upon the full redemption of this Note. Provided however that upon completion of a Qualified
Offering, the entire outstanding balance of the Note will be due and payable at closing of the Qualified Offering.

 

	 	b)
  	Monthly Redemption Amount. The definition of “Monthly Redemption Amount” set forth in Section 1 of the Note is deleted in its entirety and hereby replaced with the following:

 

“Monthly
Redemption Amount” means, as to a Monthly Redemption, one fifth of the original principal amount at 110% of such principal
amount, plus accrued but unpaid interest, liquidated damages and any other amounts then owing to the Holder in respect of this Note.

 

	 	c)	The interest on the Note that is due and payable on October 2, 2022, shall
instead be due and payable on the earlier of (i) November 2, 2022 and (ii) the closing of the Qualified Offering.
	 	 	 
	 	d)	In further consideration for extending by one month the straight-line
amortization payment requirement under the Note, the Company agrees that (i) the number of shares underlying the Warrant shall be increased
from 24,761,905 shares to 26,666,667 shares and (ii) upon the closing of Company’s offering being registered pursuant to the S-1
Registration Statement (Registration. No. 333-264339), the outstanding principal balance, along with any accrued interest, fees or costs,
will be repaid, in full pursuant to either the Optional Redemption provisions contained in Section 5(a) of the Note or the Mandatory Prepayment
provisions contained in Section 5(d) of the Note, as the case may be.

 

    	 

     

    

 

Each
of the undersigned has caused this Amendment to be duly executed and delivered as of the date first written above and will become effective
as of the Effective Date.

 

	 	CURATIVE BIOTECHNOLOGY, INC.
	 	 	 
	 	By:	 
	 	Name:	Richard
    Garr                  
	 	Title:	Chief
    Executive Officer

 

	 	Puritan Partners LLC
	 	 	 
	 	By:	 
	 	Name:	Richard
    Smithline
	 	Title:	Managing
    MemberExhibit
10.26

 

Fourth
Amendment to Transaction Documents

 

This
Second Amendment to the Transaction (this “Amendment”) is effective as of November 2, 2022 (“Effective Date”),
by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology,
Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate Blvd., Suite
110 Boca Raton, FL 33431, each a “Party” and collectively the “Parties”. Capitalized terms used
herein without definition shall have the meanings ascribed to them in the Securities Purchase Agreement, dated as of March 2, 2022, as
amended, entered between the Parties (the “Securities Purchase Agreement”)

 

Recitals

 

WHEREAS,
pursuant to the Transaction Documents, Puritan Partners purchased a 12.5% Original Issue Discount Senior Secured Note in the
principal amount of $1,142,857.14 due March 2, 2023 (the “Note”) and was issued a common stock purchase warrant to
initially purchase 22,857,143 shares of the common stock at $0.0001 exercise price (the “Warrants”);

 

WHEREAS,
Puritan Partners and Company are parties to the Transaction Documents, which were previously amended on August 18, 2022, October 2, 2022 and October 14, 2022, and the parties
now desire to further amend the respective Transaction Documents in accordance with the terms of this Amendment.

 

NOW,
THEREFORE, in consideration of the following and other consideration, the receipt of which is hereby acknowledged, the parties agree
as follows:

 

		(a)	Monthly
                                            Redemption Date. The definition of “Monthly Redemption Date” set forth in Section
1 of the Note is deleted in its entirety and hereby replaced with the following:

 

“Monthly
Redemption Date” means the second of each month commencing in November 2022; provided that the first Monthly Redemption Date
shall be November 17, 2022, and terminating upon the full redemption of this Note. Provided however that upon completion of a Qualified
Offering, the enter outstanding balance of the Note will be due and payable at closing of the Qualified Offering.

 

		(b)	The
                                            interest on the Note that is due and payable on November 2, 2022, shall instead be due and
                                            payable on the earlier of (i) November 17, 2022 and (ii) the closing of the Qualified Offering.
	 	 	 
	 	(c)	In determining the price per share of common stock sold in the Qualified
Offering for purposes of Section 3(b) of the Warrant, the warrants issued as part of the units sold in the Qualified Offering shall be
valued at the Black Scholes Value thereof (as defined in Section 3 the Warrant) which the parties agree is $4.26 per warrant. Thus in
determining the price per share of common stock sold in the Qualified Offering, the Black Scholes Value of the warrant sold in the Qualified Offering shall be subtracted
from the price of the unit (assuming the unit consists of an equivalent number of shares and warrants).

 

	 	(d)	Qualified Offering. The definition of “Qualified Offering”
set forth in Section 1.1 of the Securities Purchase Agreement (and as referenced in the other Transaction Documents) is deleted in its
entirety and hereby replaced with the following:

 

“Qualified
Offering” means a debt (including convertible debt) or equity financing of either the Company or its Subsidiary’s securities
resulting in aggregate gross proceeds to the Company of at least $ 7,200,000 (or such lesser amount in an equity offering by Aegis Capital
or its affiliates). For purposes of clarity, to qualify as a Qualified Offering, the gross proceeds must be raised in one (1) offering
(which may have one or several closings) and the proceeds of multiple offerings of securities with different terms will not be aggregated
together.

 

[Remainder
of Page Intentionally Left Blank]

 

    	 

     

    

 

Each
of the undersigned has caused this Amendment to be duly executed and delivered as of the date first written above and will become effective
as of the Effective Date.

 

	 	CURATIVE BIOTECHNOLOGY, INC.
	 	 	 
	 	By:	 
	 	Name:	Richard
    Garr                  
	 	Title:	Chief
    Executive Officer

 

	 	Puritan Partners LLC
	 	 	 
	 	By:	 
	 	Name:	Richard
    Smithline
	 	Title:	Managing
    Member

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]